eyecro data to be presented at ARVO 2016 in Seattle
Similar Posts
Groundbreaking Research Published in Collaboration with the National Eye Institute
We are thrilled to announce the publication of our latest research in eLife. This milestone represents an inspiring collaboration between EyeCRO and the esteemed laboratory of Dr. Anand Swaroop at the National Eye Institute. Our partnership exemplifies how teamwork and shared vision can advance the frontiers of science and medicine, particularly in the development of…
New Insights into Optic Nerve Injury Treatment with Brain-Derived Neurotrophic Factor (BDNF)
In the article “Assessment of Brain-Derived Neurotrophic Factor on Retinal Structure and Visual Function in Rodent Models of Optic Nerve Crush,” published in Pharmaceuticals, Volume 17, Issue 6 (June 2024), scientists explored the impact of BDNF on retinal structure and visual function. The study focused on rodent models to investigate how BDNF affects retinal ganglion…
Partnership Aims to Take Advantage of Preclinical Ophthalmology Developments
Rafal Farjo, PhD, COO of eyecro, told Outsourcing-pharma.com that the “demand for ophthalmology studies is increasing. Many research scientists are uncovering new mechanisms and targets for ophthalmic disease, it is also becoming apparent that there is pathology in common with many other clinical indications. eyecro specializes in ophthalmic studies of preclinical efficacy, pharmacokinetics, toxicology, and…
eyecro co-authors paper in Molecular and Cellular Biology studying mechanisms leading to Diabetic Retinopathy
Serum retinol-binding protein (RBP4) is the sole specific transport protein for retinol in the blood, but it is also an adipokine with retinol-independent, pro-inflammatory activity associated with obesity, insulin resistance, type 2 diabetes, and cardiovascular disease. Here we show that RBP4-Tg mice develop progressive retinal degeneration, characterized by photoreceptor ribbon synapse deficiency and subsequent bipolar…
EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model. Click here to read more
EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease
Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 eyecro and MPI Research, two global leaders in preclinical ophthalmology contract research, today announced a collaboration to develop and commercialize large mammalian preclinical models for various ophthalmic diseases, including Age-Related Macular Degeneration and Diabetic Retinopathy. The partnership leverages the unique skills and…
